Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data drop
Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data drop
Structure Therapeutics
Structure Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for serious diseases, with a lead program (GSBR-1290) in oral GLP-1 receptor agonism for obesity and type 2 diabetes. The company's pipeline targets GPCR-driven metabolic and cardiopulmonary diseases, leveraging structure-based drug design to create differentiated oral alternatives to injectable peptide therapies.
Company Info
Sector:Biotechnology / Small-Molecule Metabolic Disease
Headquarters:South San Francisco, California, USA
Founded:2017
Website:structuretx.com/
Upcoming Milestones & Key Dates
H2 2026
Regulatory
End-of-Phase 2 meeting with FDA on GSBR-1290 obesity program
Late 2026 / 2027
Clinical Trial
GSBR-1290 Phase 3 initiation in obesity
Clinical Development Pipeline
GSBR-1290
Target: Oral small-molecule GLP-1 receptor agonistANPA-0073
Target: Apelin receptor agonistLTSE-2578
Target: Lysophosphatidic acid receptor 1 (LPA1) antagonistRecent News
ADA: AstraZeneca Hands Structure a Win With 'Relatively Underwhelming' GLP-1 Pill Data
Structure Therapeutics' oral GLP-1 pill produced a 'relatively underwhelming' but still positive Phase 2 readout in diabetes, with analysts questioning commercial viability against Lilly's Foundayo and Novo's Wegovy pill.
Leadership Team
Ray Stevens
Chief Executive Officer